



Press/Investor Contact: CHARLES TRIANO
Vice President, Investor Relations
Forest Laboratories, Inc.
909 Third Avenue
New York, NY 10022
(212) 224-6714
Charles.Triano@frx.com

Physician Contact: Professional Affairs
1-800-678-1605 (Ext 7301)

Oral Solution Formulation of Namenda®, the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Available

NEW YORK, NY – August 18, 2005 – Forest Laboratories, Inc. (NYSE: FRX) announced today that an oral solution formulation of Namenda® (memantine HCl), the only FDA-approved treatment for moderate to severe Alzheimer's disease, is now available to physicians, patients, and pharmacies nationwide. Oral solution offers an alternative that may make administration of Namenda easier for those patients who have trouble swallowing tablets, and for those who prefer taking medication in liquid form.

The oral solution of Namenda is equivalent on a milligram per milligram basis to the Namenda tablets and is administered in the same manner. Namenda oral solution is available in a 2 mg/ml concentration, 360 ml (12 oz) bottle.

About Namenda

Namenda (memantine HCl) is the first in a class of medications with a unique mechanism of action that focuses on the glutamate pathway, a target for the treatment of Alzheimer's disease. Indicated for the treatment of moderate to severe Alzheimer's disease, the FDA approved Namenda (October 2003) based on three studies of Namenda used alone or in combination with another Alzheimer's disease drug.

Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.

About Forest Laboratories and Its Products

Forest Laboratories' growing line of products includes: Lexapro® (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda® (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar® (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar HCT® (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral® (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with

alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; and Combunox™(Oxycodone HCl and Ibuprofen), an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2005 and on form 10-Q for the periods ended June 30, 2005. Actual results may differ materially from those projected.

*Benicar is a registered trademark of Sankyo Pharma Inc.; Campral is a registered trademark under license from Merck Santé s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Forest Laboratories markets Namenda® (memantine HCl) in the United States under license from Merz Pharma GmbH & Co. of Germany. Lundbeck, under license from Merz, markets memantine as Ebixa®, and Merz markets memantine as Axura® and as Akatinol®, each in a number of markets worldwide. Ebixa, Axura, and Akatinol are registered trademarks Merz Pharma GmbH & Co.

###